🇺🇸 FDA
Pipeline program

Low Dose ARD-501

AARD-501.2

Phase 2 small_molecule completed

Quick answer

Low Dose ARD-501 for Autism Spectrum Disorder is a Phase 2 program (small_molecule) at Aardvark Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aardvark Therapeutics
Indication
Autism Spectrum Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials